l e t t e r s nature medicine VOLUME 18 | NUMBER 6 | JUNE To identify this putative KSHV receptor, we surface-biotinylated sog9 cells 17 , lysed them and subjected the lysate to immunoprecipitation with a soluble variant of gH lacking the transmembrane and intracellular part fused to the Fc fragment of human IgG (gH∆TM-Fc) that was co-expressed in complex with gL (gH∆TM-Fc/gL) (Fig. 1a) . We identified by mass spectrometry a membrane protein of ~110 kDa that specifically interacted with this glycoprotein complex as EphA2 (Supplementary Table 1) . Immunoprecipitation with gH∆TM-Fc/gL from 293T human embryonic kidney cells expressing Myc-and Histagged EphA2 lacking the intracellular domain (EphA2∆ICMycHis) confirmed this interaction (Fig. 1b) . Soluble EphA2 also bound to 293T cells expressing KSHV gH-gL (Supplementary Fig. 1 ). However, only KSHV gH-gL precipitated EphA2 whereas gH-gL from the related rhesus monkey rhadinovirus (RRV) did not (Fig. 1c) . Co-sedimentation experiments were performed using KSHV virions concentrated from the supernatant of the KSHV-positive primary effusion lymphoma (PEL) cell line BC3 to further prove that EphA2 is associated with gH-gL in the virion envelope. The recombinantly expressed hemagglutinin-tagged ectodomain of EphA2 (EphA2-HA) was incubated with precleared supernatant from BC3 cells that were either induced to produce KSHV virions or left uninduced (mock). KSHV virions were then pelleted by centrifugation and subjected to western blot analysis. The virion envelope protein gpK8.1 did not bind directly to EphA2 (data not shown). Due to alternative splicing and glycosylation, different forms of the viral envelope glycoprotein gpK8.1 are expressed in cells lytically infected with KSHV. The predominant
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma 1 , a highly vascularized tumor originating from lymphatic endothelial cells, and of at least two different B cell malignancies 2, 3 . A dimeric complex formed by the envelope glycoproteins H and L (gH-gL) is required for entry of herpesviruses into host cells 4 . We show that the ephrin receptor tyrosine kinase A2 (EphA2) is a cellular receptor for KSHV gH-gL. EphA2 co-precipitated with both gH-gL and KSHV virions. Infection of human epithelial cells with a GFP-expressing recombinant KSHV strain, as measured by FACS analysis, was increased upon overexpression of EphA2. Antibodies against EphA2 and siRNAs directed against EphA2 inhibited infection of endothelial cells. Pretreatment of KSHV with soluble EphA2 resulted in inhibition of KSHV infection by up to 90%. This marked reduction of KSHV infection was seen with all the different epithelial and endothelial cells used in this study. Similarly, pretreating epithelial or endothelial cells with the soluble EphA2 ligand ephrinA4 impaired KSHV infection. Deletion of the gene encoding EphA2 essentially abolished KSHV infection of mouse endothelial cells. Binding of gH-gL to EphA2 triggered EphA2 phosphorylation and endocytosis, a major pathway of KSHV entry 5, 6 . Quantitative RT-PCR and in situ histochemistry revealed a close correlation between KSHV infection and EphA2 expression both in cultured cells derived from human Kaposi's sarcoma lesions or unaffected human lymphatic endothelium, and in situ in Kaposi's sarcoma specimens, respectively. Taken together, our results identify EphA2, a tyrosine kinase with known functions in neovascularization and oncogenesis, as an entry receptor for KSHV.
Herpesvirus entry involves several viral glycoproteins and cellular receptors 4, 7 . KSHV uses cell surface heparan sulfate [8] [9] [10] [11] or DC-SIGN 12 for attachment. Subsequently, KSHV binding to integrins activates several downstream effectors 13, 14 followed by endocytosis 5, 6 . The cysteine transporter xCT was identified as a fusion receptor for KSHV 15 . However, the viral glycoproteins responsible for interactions with xCT have not been identified. In the case of KSHV, gB and gH-gL seem to comprise the minimal fusion machinery 16 . We previously reported that the gH-gL complex binds an unknown receptor on the heparan sulfate-negative mouse fibroblast cell line sog9 (ref. 11) .
To identify this putative KSHV receptor, we surface-biotinylated sog9 cells 17 , lysed them and subjected the lysate to immunoprecipitation with a soluble variant of gH lacking the transmembrane and intracellular part fused to the Fc fragment of human IgG (gH∆TM-Fc) that was co-expressed in complex with gL (gH∆TM-Fc/gL) (Fig. 1a) . We identified by mass spectrometry a membrane protein of ~110 kDa that specifically interacted with this glycoprotein complex as EphA2 (Supplementary Table 1 ). Immunoprecipitation with gH∆TM-Fc/gL from 293T human embryonic kidney cells expressing Myc-and Histagged EphA2 lacking the intracellular domain (EphA2∆ICMycHis) confirmed this interaction (Fig. 1b) . Soluble EphA2 also bound to 293T cells expressing KSHV gH-gL (Supplementary Fig. 1 ). However, only KSHV gH-gL precipitated EphA2 whereas gH-gL from the related rhesus monkey rhadinovirus (RRV) did not (Fig. 1c) . Co-sedimentation experiments were performed using KSHV virions concentrated from the supernatant of the KSHV-positive primary effusion lymphoma (PEL) cell line BC3 to further prove that EphA2 is associated with gH-gL in the virion envelope. The recombinantly expressed hemagglutinin-tagged ectodomain of EphA2 (EphA2-HA) was incubated with precleared supernatant from BC3 cells that were either induced to produce KSHV virions or left uninduced (mock). KSHV virions were then pelleted by centrifugation and subjected to western blot analysis. The virion envelope protein gpK8.1 did not bind directly to EphA2 (data not shown). Due to alternative splicing and glycosylation, different forms of the viral envelope glycoprotein gpK8.1 are expressed in cells lytically infected with KSHV. The predominant
The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus variant of gpK8.1 that is present in cellular membranes migrates with an apparent molecular weight of 35-37 kDa. In contrast, a protein of 68-72 kDa is selectively incorporated into the virion envelope 18 . Co-sedimentation of EphA2-HA with a gpK8.1 protein of 68-72 kDa 18 and not the cell-membrane variant of 35 kDa demonstrated association of EphA2 with virions (Fig. 1d) . Having shown that soluble EphA2 is able to bind both isolated gH-gL (Fig. 1b,c and Supplementary Fig. 1 ) and KSHV (Fig. 1d) , we next examined whether gH-gL is able to bind membrane-bound EphA2. We added heparin to the recombinantly expressed gH-gL glycoprotein complex to inhibit binding of gH-gL to heparan sulfate 11 . We incubated mouse pulmonary microvascular endothelial cells (MPMECs) from either an Epha2-knockout mouse or the parental mouse strain (WT) with gH∆TM-Fc/gL. Binding of gH∆TM-Fc/gL to WT MPMECs in the presence of heparin was clearly detectable, whereas MPMECs from an Epha2-knockout mouse 19 did not bind gH∆TM-Fc/gL (Fig. 1e) . Overexpression of EphA2 greatly increased binding of gH∆TM-Fc/gL to 293T cells (Fig. 1e) , whereas competition with soluble EphA2-Fc reduced binding of gH∆TM-Fc/gL to these cells (Fig. 1f) . This finding is particularly noteworthy because heparin was not used here (Fig. 1f) , and both gH alone and the gH-gL complex bind cell-surface heparan sulfates with high affinity 11 .
The inhibition of the interaction of gH∆TM-Fc/gL with the cell surface by soluble EphA2 (Fig. 1f) 23 ), EphA2-Fc inhibited KSHV infection in a dose-dependent manner by up to 97% (Fig. 2a and Supplementary Fig. 2 ). Half-maximal inhibition of KSHV infection was achieved at a concentration of <0.2 µg ml −1 , which corresponds to approximately 1 nM of dimeric EphA2-Fc (Fig. 2a) . A recombinant herpesvirus saimiri serving as a control was unaffected by EphA2-Fc (Supplementary Fig. 3a) .
In addition to blocking the EphA2 binding site(s) on KSHV virions with soluble EphA2 (Fig. 2a and Supplementary Fig. 2 ),we also blocked EphA2 on primary human umbilical vein endothelial cells (HUVECs) and primary human LECs with a polyclonal antibody against EphA2 before KSHV infection, resulting in a significant reduction of KSHV infection ( Fig. 2b , P < 0.001). In contrast to KSHV infection, infection with herpesvirus saimiri was not inhibited by EphA2-specific antibody (Supplementary Fig. 3b ). Overexpression of EphA2 in two human epithelial cell lines (293T and H1299) resulted in increased KSHV infection (Supplementary Fig. 4) . We confirmed the relevance of EphA2 in infection of endothelial cells by RNAi (Fig. 2c) ; siRNA against EphA2 specifically reduced infection of LECs by approximately 70% (nonsense siRNA siNon versus siEphA2, Student's t test, P < 0.05). Silencing of EphA2 was verified by FACS analysis (Supplementary Fig. 5 ).
We performed additional control experiments using (i) soluble EphA2 without the Fc tag, (ii) the closely related protein EphA5, (iii) the soluble EphA2 ligand ephrinA4-Fc, which induces EphA2 signaling, (iv) preincubation of the cells, rather than KSHV, with EphA2 and (v) soluble integrins and heparin for comparison (Fig. 2d,e) . The GFP-expressing rKSHV.219 was used again. We determined infection rates by FACS analysis for GFP expression and by quantitative real time-PCR (qRT-PCR) for the KSHV latency-associated nuclear antigen-1 (LANA-1) transcript. Preincubation of KSHV with EphA2-Fc or monomeric EphA2, in contrast to preincubation with the closely related EphA5, resulted in a significant reduction of infection that was comparable to the inhibitory effect of the virion-attachment inhibitor heparin, as did preincubation of the cells with ephrinA4-Fc (Fig. 2d) . Surprisingly, in contrast to data from other groups [5] [6] [7] 14 
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( Fig. 2d) . The discrepancy between these results and previously published work [5] [6] [7] 14 may reflect cell-specific usage of integrins by KSHV, and the role of integrins in the infection of endothelial cells and cells derived from Kaposi's sarcoma has not been examined so far. In summary, these data indicated that the observed inhibition of KSHV infection is specific for EphA2. However, it remained to be shown that this inhibitory effect is mediated by the interaction of EphA2-Fc with the KSHV virion and not the cell. Thus, we incubated either KSHV or the cells with EphA2-Fc 30 min prior to infection. We used soluble Fc as a control. Compared to both Fc pretreatment or the buffer control (KSHV only), only pretreatment of the viral inoculum with EphA2-Fc at 2 µg ml −1 resulted in a statistically significant reduction in KSHV infection (Fig. 2e) . In contrast to the EphA2 ligand ephrinA4-Fc ( Fig. 2d) , soluble EphA2-Fc did not result in reduced infection when added to the cells (Fig. 2e) . This shows that inhibition of infection by EphA2 requires the interaction of EphA2 with the KSHV virion. Infection of MPMECs with rKSHV.219 resulted in 25% infected cells at 3 d after infection. Preincubation of the virus with EphA2-Fc reduced infection by about 90% (Fig. 2f) . MPMECs from an Epha2-knockout mouse were almost completely resistant to KSHV infection (Fig. 2f) . When we reconstituted EphA2 expression in these knockout cells by a retroviral expression vector 19 , MPMECs from the EphA2 −/− mouse regained permissiveness (Fig. 2f) .
Although many cell lines can be infected by KSHV, permissiveness for KSHV entry varies as reflected by the percentage of cells infected using a constant MOI 24 , as does expression of EphA2. We measured EphA2 mRNA expression levels by qRT-PCR in ten different types of primary human cells and human cell lines. EphA2-Fc (2 µg ml −1 ) diminished KSHV infection by at least 50% in all cell lines examined (Supplementary Fig. 6 ). Plotting EphA2 mRNA expression against the infection rate revealed a linear correlation (Pearson's r = 0.95, P = 0.014) for cells of lymphatic endothelial origin (Fig. 2g) . Notably, the permissiveness of two different batches of LECs varied about twofold (LEC and LEC-hi), which was reflected by the corresponding EphA2 expression.
To assess the effect of KSHV on EphA2 activation, we incubated 293T cells with concentrated supernatants either from 293 cells producing recombinant KSHV strain rKSHV.219 or uninfected control cells. EphrinA1-Fc was used as a positive control. Both rKSHV.219 and the natural EphA2 ligand ephrinA1 recombinantly expressed in fusion to the Fc (ephrinA1-Fc) increased EphA2 phosphorylation ( Fig. 3a and Supplementary Fig. 7 ). EphA2 phosphorylation was reverted when KSHV was preincubated with EphA2-Fc (Fig. 3b) . Next, we stimulated cellular EphA2 with gH∆TM-Fc/gL. Crosslinking of gH∆TM-Fc/gL through an Fc-specific antibody was required for activation of EphA2 (data not shown), mimicking higher-order clustering of envelope glycoproteins. Treatment of cells with crosslinked gH∆TM-Fc/gL or ephrinA1-Fc resulted in a marked increase in EphA2 phosphorylation, as detected by western blot (Fig. 3c) . To determine whether these effects are of biological importance for KSHV entry, we transiently overexpressed either full-length EphA2 or EphA2 without the intracellular kinase domain (EphA2∆ICMycHis) in 293T cells. We confirmed equal surface expression by FACS analysis (Supplementary Fig. 8 ). Overexpression of full-length EphA2, but not EphA2∆ICMycHis, enhanced KSHV infection in the total cell population by more than 70% (Fig. 3d) . We detected a threefold increase in KSHV infection when the analysis was limited to those cells positive for the Myc-tagged EphA2 constructs (Fig. 3d) .
To ascertain whether EphA2 is able to mediate uptake of gH∆TM-Fc/gL, we transiently expressed Myc-tagged EphA2 in HeLa cells. We incubated the cells with cross-linked gH∆TM-Fc/gL at 4 °C before analyzing the localization of both EphA2 and gH∆TM-Fc proteins by immunofluorescence. Directly after incubation at 4 °C, EphA2 and gH∆TM-Fc/gL colocalized at the membrane, whereas after a shift to 37 °C for 60 min both proteins colocalized at vesicular structures within the cell (Fig. 3e) . We performed additional experiments to confirm that gH∆TM-Fc/gL is endocytosed in a fashion analogous to ephrinA1-Fc (Supplementary Fig. 9) .
Finally, we examined EphA2 expression in tissue sections from individuals with Kaposi's sarcoma. We stained for the latent KSHV antigen LANA-1 and for EphA2 in consecutive sections of tissues from the skin (n = 14) or the lung (n = 1) from 15 individuals with AIDS and Kaposi's In all Kaposi's sarcoma tissues, LANA-1 and EphA2 were expressed in the Kaposi's sarcoma spindle cells (Fig. 4a-f ). Kaposi's sarcoma skin tissues showed increased numbers of KSHV-positive cells compared to uninvolved skin from the same individual (Fig. 4a,c) , and we detected increased EphA2 staining in the respective consecutive sections (Fig. 4b,d) . We also detected numerous KSHV-infected cells in lung Kaposi's sarcoma tissue (Fig. 4e) . In lung Kaposi's sarcoma, EphA2 staining resembled the distribution of LANA-1 and both proteins were less homogeneously distributed than in skin Kaposi's sarcoma tissue (Fig. 4f) . We used breast carcinoma tissue as a positive control for EphA2 detection (Fig. 4g) . Uninvolved skin tissues from the same KS patient stained only slightly positive for EphA2 in the epithelial cells of the epidermis (Fig. 4h) and stained negative for LANA-1 (Fig. 4i) . Thus, the percentage of KSHV-infected, LANA-1-positive cells was reflected by the percentage of EphA2-expressing cells. Whereas hardly any EphA2-positive cells were detectable in uninvolved and KSHVnegative skin, the expression of EphA2 was greatly increased in Kaposi's sarcoma specimens from lung and skin, which was paralleled by the number of KSHV-infected cells. In contrast to cells in uninvolved skin, the epidermal cells of the skin overlaying Kaposi's sarcoma tissue were strongly positive for EphA2, suggesting an induction of EphA2 expression in the Kaposi's sarcoma-associated micromilieu (Fig. 4b,d) . This study has shown that EphA2 directly interacts with gH and gL of KSHV. Moreover, interference with this interaction by antibodies against EphA2, by soluble EphA2 ligands, by siRNA-mediated knockdown of EphA2 or by competition with soluble EphA2, but not by closely related Eph proteins, unequivocally inhibited KSHV infection, whereas overexpression of EphA2 enhanced it. Moreover, we showed a strong correlation between EphA2 expression and KSHV infection both in cultured Kaposi's sarcoma-derived cells and in Kaposi's sarcoma tissues (Figs. 2g and 4, respectively) . Knockout of both Epha2 alleles in mice essentially abrogated KSHV infection of mouse endothelial cells (Fig. 2f) . Recently, EphA2 was identified as a cellular co-factor for hepatitis C virus (HCV) entry 25 , organizing other receptors on the cell surface to facilitate virus entry. Thus, the role for EphA2 in the case of HCV infection is mechanistically different, as it seems not to function as a receptor. Still, phosphorylation of EphA2 (Fig. 3a-c ) may contribute to KSHV entry by membraneorganizing effects similar to those described for HCV 25 .
Herpesviral gH-gL proteins mediate entry and fusion, sometimes in a cell-specific manner [26] [27] [28] [29] [30] and in concert with other viral glycoproteins 4 . Unexpectedly, the crystal structures of gH-gL from two herpesviruses, herpes simplex virus and Epstein-Barr virus, did not resemble other viral fusion proteins 31, 32 . KSHV gH-gL has been shown to be required for fusion 16 , but further work will be required to define the exact steps of viral entry involving KSHV gH-gL and EphA2. EphA2 ligand binding results in receptor clustering and endocytosis 33, 34 , as does binding of preclustered gH-gL ( Fig. 3e and Supplementary Fig. 9 ). Thus, KSHV mimics ligand-induced activation of EphA2 and may profit from this endocytotic stimulus.
We clearly demonstrate a crucial role of EphA2 in KSHV infection of endothelial cells, the cells from which Kaposi's sarcoma originates 35 , and show that EphA2 is highly expressed in Kaposi's sarcoma tissue sections (Fig. 4a-f) . EphA2, EphA4 and EphB2 are known to be phosphorylated in Kaposi's sarcoma tissues 36, 37 , and EphA2 activation is an important factor in angiogenesis 36, 38 . In turn, Kaposi's sarcoma is an angiogenic tumor characterized by chronic, ongoing KSHV infection and neovascularization. The known proangiogenic properties of EphA2 together with the findings of this study support the hypothesis that KSHV interaction with EphA2 is implicated in Kaposi's sarcoma pathogenesis.
Therapeutic synergies between inhibiting viral entry and blocking angiogenesis by targeting EphA2 may be beneficial in the treatment of this disease.
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Methods and any associated references are available in the online version of the paper.
oNLINE METHoDS
Cells, virus, plasmids, transfection and recombinant protein production. Adherent cell lines were cultivated in DMEM supplemented with 10% FBS and gentamycin at 37 °C, 7% CO 2 at 80% humidity. Human LECs and mouse 39 endothelial cells were cultivated in EGM-2 MV (Lonza). Lung microvascular endothelial cells were isolated from WT and Epha2-knockout mice as described before 39 . Transduction with LZRS retrovirus expressing WT EphA2 has been described earlier 39 . All mice were housed under pathogen-free conditions, and experiments were performed in accordance with the Association and Accreditation of Laboratory Animal Care International guidelines and with approval by the Vanderbilt University Institutional Animal Care and Use Committee. Human LECs were purchased from Lonza. HUVECs were purchased from Promocell and maintained in endothelial cell growth medium (Promocell). KSImm cells were kindly provided by A. Albini. SLK 40 43 . rKSHV.219 44 virus preparation and infection assays were carried out essentially as described previously 45 . Tangential flow filtration followed by diafiltration against PBS was used as the first step to concentrate and purify KSHV virions from the supernatant of lytically induced cells in a protocol modified from reference 46. Briefly, the minimate system (PALL Life Sciences) and tangential flow filtration capsules with a cutoff of 300 kDa were used according to the manufacturer's instructions. A transmembrane pressure of 1 bar was used at a flow rate of 80 ml min −1 . Further virus purification was performed by centrifugation on Opti-Prep (iodixanol) gradients 47 . For KSHV infections at low titer, supernatant from rKSHV.219-producing 293 cells was concentrated by centrifugation as previously described 48 . Unless stated otherwise, KSHV was used at a multiplicity of infection of 0.5 as determined on SLK cells. For infection of MPMECs, an SLK multiplicity of infection of 2 was used. A recombinant, GFP-expressing clone of herpesvirus saimiri (HVS-M45) was generated by recombination of five overlapping cosmids 49 . Here, the HVS oncogenes stpC and tip were deleted by digestion of cosmid 331EGFP (ref. 50) with Bst1107I, followed by religation, yielding cosmid 331EGFP-∆StpC/Tip. Blocking of infection with soluble receptor was assayed by a 30-min preincubation of the virus dilution at room temperature with EphA2-Fc or Fc at 2 µg ml −1 if not indicated otherwise and subsequent infection. Recombinant Fc-fusion proteins were prepared as described previously 51 . Strep-tagged versions of gH∆TM-Fc and Fc were purified under native conditions by StrepTactin chromatography and elution with 3 mM biotin in PBS. Soluble EphA2-Fc comprises amino acids 25-534 of human EphA2 in the pAB61 Fc-fusion backbone vector. Soluble EphA2-HA comprises amino acids 1-534 fused to the hemagglutinin epitope in the pcDNA6 backbone. EphrinA1-Fc comprises amino acids 19-188 of human ephrinA1 (EFNA1) in the pAB61 Fc-fusion backbone vector. Expression plasmid pEphA2MycHis (full length, ref|NP_004422.2|) was generated by PCR amplification of the respective fragment from EphA2 cDNA. The resulting amplicon was inserted into the pcDNA4a backbone. An antiserum against EphA2 was raised in rabbits using recombinant soluble EphA2. Whole antibodies were purified from this serum using protein A-Sepharose. For blocking purposes, polyclonal antibody was used at 1 mg ml −1 .
Transfection was carried out as described previously 48 . Stably transfected cell populations were generated by selection with 100 µg ml −1 Zeocin (Invitrogen). Octyl-β-d-glucopyranoside formulations of human integrins α 3 β 1 (catalog no. CC1029) and α V β 3 (cat. no. CC1020) were purchased from Upstate Biotechnology/Millipore. EphA2-specific monoclonal antibody D7 (catalog no. 05-480, dilution 1:500) and integrin α V β 3 -specific antibody clone LM609 (catalog no. MAB1976, used at 10 µg/ml) were purchased from Chemicon/Millipore. Recombinant human EphA2, EphA5 and ephrinA4-Fc were purchased from R&D; recombinant EphA4 was purchased from Biomol.
Surface biotinylation, immunoprecipitation and mass spectrometry. Biotinylation of cellular membrane proteins was performed with EZ-link Sulfo-NHS-Biotin (Pierce) according to the manufacturer's instructions. For immunoprecipitation, cells were lysed in 1% NP-40, 150 mM NaCl, 2.5 mM EDTA/EGTA, 20 mM HEPES pH 7.4. The lysates were cleared by centrifugation at 20,000g, and supernatants were immunoprecipitated with Fc-fusion proteins coupled to protein A-Sepharose (GE Healthcare). Coupling of proteins was achieved by preadsorbing 1 ml of protein containing supernatant per sample to the protein A-Sepharose beads. For mass-spectrometry analysis, three densely confluent 10-cm culture dishes of sog9 mouse fibroblasts were used per immunoprecipitation sample. For small-scale immunoprecipitation, approximately two million transfected 293T cells were lysed. Samples were washed three times with lysis buffer, separated on 8-16% PAA gradient gels (Invitrogen) and stained with colloidal Coomassie blue or subjected to western blot analysis. Bands were excised from the gel and prepared for mass-spectrometric identification as described earlier 52 . Briefly, the protein was digested in the gel using trypsin. The peptides were extracted and desalted for MALDI-TOF mass spectrometry (MALDImicro MX; Waters). In addition, the extract was applied to nanoLC-MS/MS using UPLC and Q-TOF Premier (Waters). Both methods independently identified EphA2 (Supplementary Table 1) .
For co-sedimentation of KSHV with EphA2, BC3 cells were induced with 3 mM sodium butyrate to produce virus or left uninduced. Supernatants were precleared for 10 min at 3,000g and then centrifuged for 6 h at 5,000g. Supernatant was aspirated down to one-tenth of the original volume. Soluble EphA2-HA was expressed in 293T cells. Supernatant of EphA2-HA-expressing cells was precleared by centrifugation at 16,000g for 10 min. Equal amounts of BC3 and supernatant from EphA2-HA-expressing cells were mixed and incubated for 2 h at room temperature, precleared for 5 min at 3,000g and pelleted for 2 h at 16,000g. The pellet was washed twice with PBS and re-pelleted for 30 min at 16,000g, followed by western blot analysis.
was determined and used to calculate relative transcript levels using the ∆∆C t method. Quantification of EphA2 and actin transcripts was done with a twostep RT-PCR and SYBR-green labeling as described before (oligonucleotides: EphA2-RT-1830-Fw: 5′-ATC CTG TGT CAC TCG GCA GAA G-3′; EphA2-RT-2038-Rev: 5′-CCT CTA GGC GGA TGA TGT TGT G-3′; Aktin-Fw: 5′-CCA TCT ACG AGG GGT ATG-3′; Aktin-Rev: 5′-CGT GGC CAT CTC TTG CTC-3′) 53 . Absolute quantification was done using a standard curve obtained from diluted plasmid DNA.
Detection of EphA2 phosphorylation. EphA2 phosphorylation in 293T cells was measured with DuoSet IC Human Phospho-EphA2 ELISA (R&D Systems). Stimulation was achieved by inoculating the cells for 10 min with rKSHV.219 (ten genome copies per cell) or an identically prepared control preparation from the supernatant of chemically induced KSHV-negative 293 cells. Alternatively, 293T cells were stimulated with either rKSHV.219, cell culture medium or purified proteins and lysed in 1% NP-40, 150 mM NaCl, 2.5 mM EDTA/EGTA, 20 mM HEPES pH 7.4 with addition of 5 mM sodium orthovanadate and 1 mM PMSF. Intrinsic EphA2 was precipitated with protein A-Sepharose preadsorbed with 50 µl of anti-EphA2 rabbit serum (Primm, rabbit immunized with EphA2-Fc). For precipitation of Myc-tagged recombinant EphA2, antibody 9E10 (American Type Culture Collection, CRL-1729) directed against the Myc epitope coupled to protein A-Sepharose was used. Immunoprecipitation was followed by western blotting against phosphotyrosine (4G10 mouse hybridoma supernatant, a kind gift from B. Biesinger) and EphA2 (Sigma, anti-EphA2 6F8 from mouse, dilution 1:1,000).
Immunofluorescence and endocytosis assay. gHTM-FcStrep/gL, ephrinA1-Fc or Fc proteins were preincubated for 30 min at room temperature with antihuman-Fc secondary antibodies (1:100) indicated in Figure 3c for crosslinking. The proteins were then incubated with cells on cover slips for 1 h at 4 °C. After a brief wash, the cells were shifted to 37 °C and subjected to immunofluorescence analysis at the time points indicated in the legend to Figure 3c . The cells were briefly rinsed with PBS three times and fixed with 3% paraformaldehyde in PBS, followed by quenching with 0.1 M glycine and permeabilization with 0.1% NP-40 in PBS for 5 min. After blocking with 2% BSA and 5% FBS in PBS, the cells were incubated with the respective antibodies where indicated for 1 h at room temperature and mounted with ProLong Gold mounting medium (Invitrogen). Images were acquired on a Leica TCS SP5 confocal laser scanning microscope in sequential scanning mode to eliminate crosstalk.
Immunohistochemistry. Kaposi's sarcoma tissues were obtained from 15 HIV-1-infected individuals with AIDS in the context of medically required diagnostic or therapeutic procedures. Informed consent was obtained from all subjects (skin KS, n = 14; lung KS, n = 1). Staining of paraformaldehyde-fixed, paraffinembedded tissue sections for EphA2 and LANA-1 were performed as previously described 54 . A rabbit polyclonal antibody directed against human EphA2 (Santa Cruz, sc-924, diluted 1:100) and a rat monoclonal antibody against LANA-1 (Tebu-bio, catalog no. 13-210-100, diluted 1:250) were used as primary antibodies. Primary antibody binding was detected using the respective Vectastain Elite ABC Kits (Vector Laboratories). For both antibodies, the citrate buffer pH 6.0 (DakoCytomation) was used for the antigen retrieval. The sections were then developed using NovaRed Substrate (Vector Laboratories) and counterstained with Hematoxylin Gill III (Merck, Darmstadt, Germany). Stained cells were photographed using an Aristoplan microscope (Leica, Wetzlar, Germany) equipped with 10× and 25× objectives and a 3CCD Exwave HAD color camera (Sony, Berlin, Germany). Control staining was performed without primary antibody and yielded negative results (data not shown).
Statistical analyses.
All results are expressed as arithmetic means. Error bars represent either s.e.m or s.d. Data were analyzed with unpaired two-tailed t tests (SPSS 16, GraphPad Prism 5).
